Company intelligence / Profile preview

Vast Medical

Durham, North Carolina, United States

Ownership: Private
Development stage: Commercial

Overview

Vast Therapeutics is developing nitric oxide-based small molecule therapies delivered via inhalation to treat chronic respiratory diseases. Their lead programs are in preclinical and early clinical stages targeting cystic fibrosis, non-CF bronchiectasis, NTM disease, and COPD. The approach aims to break the cycle of infection and inflammation with novel antimicrobial agents that are not susceptible to traditional resistance mechanisms. No published clinical results yet.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small moleculeNitric oxide prodrugAerosolized therapy
Industry: Biotech

Partnerships

University of North Carolina at Chapel Hill [academic collaboration/founder affiliation noted in leadership bio].

Beyond the preview

Go deeper on Vast Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vast Medical.

Explore the full profile